| Deal value | $150M |
|---|---|
| Share of market cap | 8.8% |
Key highlights
- Offering of 15,000,000 shares of common stock at a public price of $10.00 per share
- Total expected net proceeds of approximately $140.4 million after expenses
- Underwriters granted a 30-day option to purchase up to 2,250,000 additional shares
- Bookrunning managers include Leerink Partners, Morgan Stanley, and Evercore ISI
- Closing of the offering is scheduled for November 16, 2026
What Is the Capital Raise?
Vir Biotechnology entered into an underwriting agreement on November 12, 2026, to sell 15 million shares of common stock in an underwritten public offering priced at $10.00 per share. The transaction, managed by bookrunners Leerink Partners, Morgan Stanley, and Evercore ISI, is expected to close by November 16, 2026, pending customary conditions. Additionally, the company granted underwriters a 30-day option to purchase up to 2.25 million additional shares at the same price. This offering leverages an effective shelf registration statement on Form S-3ASR filed concurrently with the SEC to facilitate immediate access to capital markets.
Strategic Rationale
The timing of this $150 million raise coincides with Vir's clinical advancement in chronic hepatitis delta and solid tumor oncology. By securing capital at a $10.00 price point, the company strengthens its liquidity profile to support its pipeline of PRO-XTEN dual-masked T-cell engagers. This influx of capital allows for sustained investment in research and development without immediate reliance on milestone-based debt. The offering follows a period of market volatility where the stock experienced significant price adjustments, suggesting a move to stabilize the balance sheet and provide a multi-year runway for current trial cycles.
Business Overview
- Vir Biotechnology operates as a clinical-stage biopharmaceutical firm specializing in infectious diseases and oncology
- The company’s portfolio features programs targeting chronic hepatitis delta virus (HDV)
- Development efforts include PRO-XTEN technology, creating dual-masked T-cell engagers for solid tumor indications
- Preclinical research is currently exploring multiple oncologic malignancies to expand the immune-system focused platform
- Headquartered in San Francisco, the firm utilizes a discovery engine to power the immune system
Financial Context
Prior to this offering, Vir Biotechnology reported annual revenue of $66.52 million against a market capitalization of approximately $1.71 billion. The company anticipates net proceeds of $140.4 million after deducting underwriting discounts, commissions, and estimated expenses. If the underwriters exercise their full over-allotment option, net proceeds could reach $161.5 million. Current technical indicators show a Relative Strength Index of 40.5, placing the stock in a neutral zone. This capital infusion provides a significant buffer relative to the company's current revenue profile and ongoing operational burn rate associated with late-stage clinical trials.
Down 3.8% since our story on 16 Nov: $9.96 when we broke it → $9.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $10.21 |
|---|---|
| 20 Oct | $10.74 |
| 21 Oct | $10.57 |
| 22 Oct | $10.43 |
| 23 Oct | $10.57 |
| 26 Oct | $11.04 |
| 27 Oct | $11.57 |
| 28 Oct | $11.93 |
| 29 Oct | $11.75 |
| 30 Oct | $11.30 |
| 2 Nov | $11.00 |
| 3 Nov | $11.22 |
| 4 Nov | $11.77 |
| 5 Nov | $11.02 |
| 6 Nov | $12.21 |
| 9 Nov | $13.64 |
| 10 Nov | $13.15 |
| 11 Nov | $13.13 |
| 12 Nov | $12.12 |
| 13 Nov | $9.96 |
| 16 Nov | $9.58 |
| Share price | $9.96 |
|---|---|
| Market cap | $1.7B |
| Revenue (annual) | $67M |
| 1-month price change | -4.32% |
| Sector | HealthcareBiotechnology |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Vir Biotechnology, Inc. announcing a public offering of common stock and entry into an underwriting agreement.
Track Vir Biotechnology, Inc. live
Get the next Vir Biotechnology, Inc. SEC filing seconds after it lands.





